IQVIA(US:IQV)2025-10-28 13:00Q3 2025 Financial Performance - Revenue for Q3 2025 reached $4,100 million, a 5.2% increase AFx (actual foreign exchange rates) and 3.9% increase CFx (constant currency) compared to $3,896 million in Q3 2024[12] - Adjusted EBITDA for Q3 2025 was $949 million, a 1.1% increase AFx compared to $939 million in Q3 2024[12] - Adjusted Diluted EPS for Q3 2025 was $3.00, a 5.6% increase AFx compared to $2.84 in Q3 2024[12] - Net income attributable to IQVIA Holdings Inc was $331 million in Q3 2025, compared to $285 million in Q3 2024[31] Year-to-Date (YTD) Performance - YTD Revenue for 2025 reached $11,946 million, a 4.4% increase AFx and 3.7% increase CFx compared to $11,447 million in 2024[15] - YTD Adjusted EBITDA for 2025 was $2,742 million, compared to $2,688 million in 2024[17] - YTD Adjusted Diluted Earnings per Share was $8.50, compared to $8.02 in 2024[17] Segment Performance (Q3 2025) - Technology & Analytics Solutions revenue was $1,631 million, a 5.0% increase AFx compared to $1,554 million in Q3 2024[15] - Research & Development Solutions revenue was $2,260 million, a 4.5% increase AFx compared to $2,162 million in Q3 2024[15] - Contract Sales & Medical Solutions revenue was $209 million, a 16.1% increase AFx compared to $180 million in Q3 2024[15] R&D Solutions Bookings and Backlog - R&D Solutions backlog increased by 4.1% from $31.1 billion in Q3 2024 to $32.4 billion in Q3 2025[21] Balance Sheet and Cash Flow - Cash & Cash Equivalents totaled $1,814 million[23] - Free Cash Flow for Q3 2025 was $772 million[23] Full Year 2025 Guidance - The company projects full-year 2025 revenue between $16,150 million and $16,250 million[26] - The company projects full-year 2025 Adjusted EBITDA between $3,775 million and $3,800 million[26] - The company projects full-year 2025 Adjusted Diluted EPS between $11.85 and $11.95[26]